Bataille B
Service de Neurochirurgie, CHU, Poitiers.
Neurochirurgie. 1997;43(6):372-5.
In the SFNC series (248 patients), extension of surgical resection provided no increase in survival (p = 0.04). One hundred and twenty nine patients (52.2%) receive chemotherapy in addition to radiation therapy; 60 patients (24.3%) received radiation therapy alone, and 35 patients (14.2%) chemotherapy alone. One hundred seventeen patients (48.3%) were in remission at the conclusion of the treatment. The median survival was 12 months. Actuarial survival rates for the 248 patients at 1, 2 and 5 years after diagnosis were 48%, 37% and 27%, respectively. Treatment method provided increase in survival, and radiation therapy in addition to chemotherapy significantly enhanced the duration of survival.
在SFNC系列研究(248例患者)中,扩大手术切除范围并未提高生存率(p = 0.04)。129例患者(52.2%)在接受放射治疗的同时还接受了化疗;60例患者(24.3%)仅接受了放射治疗,35例患者(14.2%)仅接受了化疗。117例患者(48.3%)在治疗结束时病情缓解。中位生存期为12个月。248例患者在诊断后1年、2年和5年的精算生存率分别为48%、37%和27%。治疗方法提高了生存率,化疗联合放射治疗显著延长了生存期。